Year: 2026
Type: article
Abstract: Chronic spontaneous urticaria (CSU) remains a therapeutic challenge in patients who fail to achieve disease control despite treatment with second-generation H1-antihistamines and, in some cases, omalizumab. Over the past two years, the therapeutic landscape of refractory CSU has evolved rapidly with the emergence of novel targeted therapies acting on distinct pathogenic pathways. This review summarizes the most relevant therapeutic advances published between 2024 and 2026 and discusses their potential implications for the future management of refractory CSU. Recent evidence indicates that Bruton tyrosine kinase (BTK) inhibitors, particularly remibrutinib, represent one of the most advanced oral therapeutic strategies currently in clinical development. Anti-KIT therapy with barzolvolimab introduces a novel approach by directly targeting mast cells, whereas dupilumab expands treatment options, especially for patients with type 2 inflammatory comorbidities. Ciclosporin remains an important therapeutic option, particularly in patients with type IIb autoimmune CSU, while additional emerging therapies further illustrate the rapid expansion of the therapeutic armamentarium. Current evidence suggests that the management of refractory CSU is progressively shifting from a stepwise empirical treatment algorithm toward a precision medicine approach based on disease endotypes, predictive biomarkers and individual patient characteristics. Future therapeutic strategies are expected to focus not only on the development of new targeted agents but also on selecting the right treatment for the right patient at the right time.
Source: Alergologia
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7225752283
